• Japanese
  • Korean
  • Chinese
Cover Image

Breast Cancer Diagnostic and Drug Technologies: Global Markets

The global market for Predictive Breast Cancer diagnostic and drug Technologies was valued at $23.4 billion in 2010 and came down to $21.2 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 2.5% and reach $24 billion by 2016.

The market for Breast cancer drugs reached $12.7 billion in 2010 and came down to $10.2 billion in 2011. The market is expected to reach $11.2 billion by 2016, a CAGR of 1.9%.

The Quantitative immunofluorescence market reached $5.7 billion in 2010 and reached to $5.9 billion in 2011. The market is expected to reach $6.9 billion by 2016, a CAGR of 3.1%.

SUMMARY FIGURE
GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND
DRUG TECHNOLOGIES, 2010 - 2016 ($ MILLIONS)

Source: BCC Research

STUDY GOALS AND OBJECTIVES

This BCC market research report provides a detailed overview and thorough analysis of the present and future global market for breast cancer diagnostics and drug technologies. It provides detailed analysis of the breast cancer drug and diagnostics markets, as well as the currently used personalized, predictive and companion tests and their markets. The research also includes market characterization, opportunities, the unmet needs associated with breast cancer, competitive assessment, product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition and the key players of the breast cancer market.

This report includes products in this market and detailed analyses of markets and competitive environments. It also analyzes current and future market prospects. It provides a comprehensive review of emerging breast cancer personalized and predictive diagnostic tests, particularly with regard to companion tests, tumor markers and gene profiling assays relevant for breast cancer prognosis and diagnosis. The analysis reviews technological developments, product innovations and recent strategic industry activity of major players across different product categories. It analyzes their strengths and weaknesses, opportunities and threats facing various devices and drugs in this market space and developments already on the market. It discusses the major issues involved in the research and development (R&D) of more effective devices for drug delivery to the lungs, along with new products in development.

REASONS FOR DOING THE STUDY

According to the National Cancer Institute, more than 200,000 women in the U.S. are diagnosed with breast cancer annually. It is no longer necessary for one breast cancer treatment to fit all cases, a concept that should be welcome news for physicians and their patients alike. Personalized medicine is relatively new to the market research report format, and it provides business tools to evaluate new commercial opportunities in diagnostics and biomarker fields. The scope of this report covers global companies developing tests relevant for breast cancer prognosis and diagnosis. This study describes current products in each area, identifies current market participants, and most importantly, notes the trends that will affect further product development in this area.

Companion diagnostics is also a part of the personalized medicine revolution. The field evolved as a continuation of biomarker studies and diagnostics testing. The breast cancer predictive testing segment of the industry is still growing; it has a number of successful FDA - approved products. This study will provide knowledge of the current state of the companion diagnostics industry and the new technologies in assay development. More importantly, it will describe potential and novel commercial developments in this area. The report will also provide an overview covering major biotechnology and pharma companies involved in developing innovative, targeted breast cancer treatments that address major unmet medical needs to advance cancer care. In addition, the report also provides information regarding the less-developed sectors of this market and presents a list of current companies that have new predictive testing products and drugs in development for breast cancer.

SCOPE AND FORMAT

This report will provide an update and on overview on predictive testing in breast cancer diagnostics and drug technologies and global markets. The study's objective is to review the tumor marker-based predictive companion tests and drugs for breast cancer, and then assess their global growth potential over a five-year period from 2011 to 2016. Review includes global markets for breast cancer incidence, current drugs, new developments, predictive diagnostic tests, market trends and new technologies, and developments and forecast trends for the use of current tests for better diagnosis and prognosis for breast cancer through 2016. Important tests, technologies and developments; market share by drug, test, current products on the market and market share by company or product; and statistical information for types of breast cancer prevalence globally, with special emphasis on the U.S. market, are discussed. The report focuses on tumor marker-based testing that provides vital information about the cancer. These tests can help determine the appropriate medicine and timing of treatment to address the disease most effectively. The report also includes current issues and trends affecting the industry. The report covers products in development, new technologies, trends, alliances, patents and mergers. It offers market data with respect to segments and geography. Other breast cancer detection and screening technologies and markets (e.g., mammography, ultrasound, biopsy) are not included in this report.

ANALYST CREDENTIALS

Usha Nagavarapu is a pharmaceutical professional with experience in scientific and alliance development. This includes more than 10 years of drug and device product development and alliance management experience. She has managed preclinical discovery programs from target identification through design of Phase I testing, including IND enabling studies, and assisted out-licensing and portfolio development activities. Strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early-start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

Table of Contents

Breast Cancer Diagnostic and Drug Technologies: Global Markets

Chapter - 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE AND FORMAT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • RELATED BCC STUDIES
  • ANALYST CREDENTIALS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

Chapter - 2: SUMMARY

  • Table Summary: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2016
  • Figure Summary: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2010 - 2016

Chapter - 3: OVERVIEW

  • BREAST CANCER DIAGNOSTICS AND TRENDS
  • BREAST CANCER
  • MAMMOGRAPHY
  • TYPES OF BREAST CANCER
  • THE FUTURE OF BREAST CANCER DETECTION

Chapter - 4: BIOMARKERS AND DEVELOPMENT OF CANCER DIAGNOSTICS

  • BIOMARKERS AND CANCER
  • BIOMARKERS AND BREAST CANCER
  • HER2
  • INCREASED USE OF BIOMARKERS IN DRUG DEVELOPMENT AND CLINICAL TRIALS

Chapter - 5: BREAST CANCER

  • SYNOPSIS
  • BREAST CANCER CAUSES
    • Table 26: SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS SUMMARY STAGE SYSTEM FOR BREAST CANCER

Chapter - 6: BREAST CANCER PREVALENCE AND INCIDENCE RATES

  • CANCER INCIDENCE ACROSS THE GLOBE
  • FAMILY HISTORY OF BREAST CANCER AND GENETIC PREDISPOSITION

Chapter - 7: BREAST CANCER DRUGS AND MARKET TRENDS

  • CLINICAL DIAGNOSIS AND MANAGEMENT
  • TRIPLE NEGATIVE BREAST CANCER
  • NEW MEDICINES FOR BREAST CANCER
  • CONCLUSIONS
    • Table 59: APPROVED ONCOLOGY DRUGS, 2012
    • Table 60: APPROVED ONCOLOGY DRUGS, 2011
    • Table 61: APPROVED ONCOLOGY DRUGS, 2010

Chapter - 8: BREAST CANCER PREDICTIVE DIAGNOSTICS MARKET

  • CANCER COSTS PROJECTED TO REACH AT LEAST $158 BILLION IN 2020
  • KEY COMPANYIES
  • GENOMIC ASSAYS
  • CONCLUSIONS

Chapter - 9: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • AETERNA ZENTARIS
  • AGENDIA
  • ALTHEADX
  • AMBERGEN INC.
  • ASTRAZENECA PLC
  • ATOSSA GENETICS INC.
  • BIOTIME
  • CCC DIAGNOSTICS LLC
  • CLARINET
  • DAKO
  • EISAI INC. (HEADQUARTERS)
  • EUTROPICS PHARMACEUTICALS
  • FLUXION BIOSCIENCES
  • GENENTECH
  • GENOMIC HEALTH
  • GLAXOSMITHKLINE
  • LIFE TECHNOLOGIES
  • MDXHEALTH
  • MERCK AND COMPANY INC.
  • MYRIAD GENETICS
  • NANOSTRING TECHNOLOGIES
  • NEKTAR
  • PFIZER
  • PHIGENIX
  • RUBICON GENOMICS
  • SANOFI US
  • VENTANA MEDICAL SYSTEMS INC.

Chapter - 10: DEVELOPMENTS AND COLLABORATIONS

  • CURRENT DEVELOPMENTS AND FUTURE

Chapter - 11: REFERENCES

List of Tables

  • Summary Table: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2016
  • Table 1: POSSIBLE SIGNS OF BREAST CANCER
  • Table 2: DIAGNOSTIC MAMMOGRAM FOR BREAST CANCER
  • Table 3: BREAST CANCER GRADES
  • Table 4: BIOPSY OR SURGERY SAMPLE TESTING
  • Table 5: TESTS USED TO EVALUATE DIFFERENT GENE SETS
  • Table 6: IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD
  • Table 7: HER2 TESTING AND VARIATIONS
  • Table 8: GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK, ASYMPTOMATIC WOMEN
  • Table 9: BREAST CANCER SCREENING RECOMMENDATIONS BY THE USPSTF
  • Table 10: BREAST CANCER PROGNOSTIC FACTORS
  • Table 11: BREAST CANCER PREDICTIVE FACTORS
  • Table 12: RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE POSITIVE FOR CANCER
  • Table 13: FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE
  • Table 14: PREDICTIVE DIAGNOSTIC FEATURES
  • Table 15: CURRENT BIOMARKER TECHNOLOGIES
  • Table 16: BIOMARKER USES
  • Table 17: MAJOR ISSUES AND CHALLENGES
  • Table 18: PHARMACOGENOMICS TESTS IN USE
  • Table 19: BIOMARKERS FOR DRUG LABELS BASED ON SPECIFIC USE
  • Table 20: CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE
  • Table 21: CLINICALLY RELEVANT BIOMARKERS
  • Table 22: APPROVED COMPANION DIAGNOSTICS, 2011
  • Table 23: REGULATORY APPROVAL OF THE DIAGNOSTICS PATHWAY
  • Table 24: APPROVED CANCER DRUGS, 2011
  • Table 25: FACTORS INFLUENCING THE CHOICE OF A DIAGNOSTICS PARTNER
  • Table 26: SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS SUMMARY STAGE SYSTEM FOR BREAST CANCER
  • Table 27: MAIN TYPES OF BREAST CANCER
  • Table 28: BREAST CANCER EVALUATION TESTS
  • Table 29: TREATMENT PLAN
  • Table 30: HORMONE THERAPY
  • Table 31: CANCER STAGES
  • Table 32: RISK FACTORS OF RECURRENCE AFTER SUCCESSFUL TREATMENT FOR BREAST CANCER
  • Table 33: BREAST CANCER PREVENTION MEASURES
  • Table 34: AMERICAN CANCER SOCIETY'S DIETARY GUIDELINES FOR CANCER PREVENTION
  • Table 35: BREAST CANCER INCIDENCE AND MORTALITY GLOBALLY, 2008
  • Table 36: ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010 - 2016
  • Table 37: NEW BREAST CANCER CASES BY GEOGRAPHIC REGION, 2009
  • Table 38: EFFECTIVE EDUCATION AND SCREENING ADVANTAGES IN THE U.K. AND THE U.S.
  • Table 39: CRUDE AND EUROPEAN AGE-STANDARDIZED BREAST CANCER INCIDENCE RATES PER 100,000 POPULATIONS IN THE U.K., 2008
  • Table 40: U.K. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016
  • Table 41: GERMAN ESTIMATED INCIDENCE OF BREAST CANCER AND PROJECTIONS, 2010-2016
  • Table 42: CHINESE ESTIMATED INCIDENCE OF BREAST CANCER, 2008 - 2016
  • Table 43: INDIA ESTIMATED INCIDENCE OF BREAST CANCER, 2008-2016
  • Table 44: JAPAN ESTIMATED INCIDENCE OF BREAST CANCER, 2010
  • Table 45: FIVE-YEAR SURVIVAL FOR BREAST CANCER
  • Table 46: BREAST CANCER FIVE-YEAR SURVIVAL BY CANCER STAGE
  • Table 47: U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
  • Table 48: U.S. ESTIMATED NEW FEMALE BREAST CANCER CASES AND DEATHS BY AGE, 2011
  • Table 49: U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2012
  • Table 50: COMPARISON OF BREAST CANCER INCIDENCE AND DEATH IN MEN AND WOMEN, 2012
  • Table 51: ESTIMATED BREAST CANCER INCIDENCE, 2004-2008, AND MORTALITY, 2003-2007
  • Table 52: BREAST CANCER ESTIMATES IN ASIAN WOMEN, INCIDENCE, 2004-2008, AND MORTALITY, 2003-2007
  • Table 53: ESTIMATED BREAST CANCER INCIDENCE IN HISPANIC AND LATINA WOMEN, 2004 - 2008, AND MORTALITY, 2003 - 2007
  • Table 54: BREAST CANCER RISK WITH AGE
  • Table 55: U.S. RATES, TRENDS AND CAUSE-SPECIFIC SURVIVAL FOR FEMALE BREAST CANCER PATIENTS BY RACE OR ETHNICITY, 2001-2007
  • Table 56: RELATIVE CANCER SURVIVAL IN WOMEN
  • Table 57: CANADA ESTIMATED NUMBER OF NEW BREAST CANCER CASES IN FEMALES BY AGE, 2010
  • Table 58: AUSTRALIA PROJECTED NEW CASES OF BREAST CANCER, 2011-2021
  • Table 59: APPROVED ONCOLOGY DRUGS, 2012
  • Table 60: APPROVED ONCOLOGY DRUGS, 2011
  • Table 61: APPROVED ONCOLOGY DRUGS, 2010
  • Table 62: DRUGS APPROVED FOR BREAST CANCER
  • Table 63: HORMONE THERAPY FOR BREAST CANCER
  • Table 64: AROMATASE INHIBITORS FOR TREATING BREAST CANCER
  • Table 65: CHEMOTHERAPY DRUGS FOR TREATING BREAST CANCER
  • Table 66: COMMONLY USED COMBINATIONS
  • Table 67: MEDICINES TO CONTROL AND PREVENT NAUSEA AND VOMITING
  • Table 68: MARKET FOR TARGETED CANCER DRUGS, 2008 AND 2016
  • Table 69: TARGETED THERAPUETICS FOR BREAST CANCER
  • Table 70: GLOBAL PHARMACEUTICAL SALES, THROUGH 2016
  • Table 71: BREAST CANCER THERAPY SALES, THROUGH 2016
  • Table 72: BREAST CANCER DRUG MARKET, 2010 AND 2016
  • Table 73: AROMATASE INHIBITORS MARKET, 2010 AND 2016
  • Table 74: BREAST CANCER TARGETED THERAPIES, 2010 AND 2011
  • Table 75: ROCHE SALES COMPARED TO THE GLOBAL MARKET, 2010
  • Table 76: XELODA SALES, 2010 AND 2011
  • Table 77: ROCHE-SALES VERSUS THE GLOBAL MARKET, 2011
  • Table 78: EXPECTED SALES FOR PERTUZUMAB, 2016
  • Table 79: CANCER THERAPY SALES, 2008 AND 2018
  • Table 80: AUSTRALIA TARGETED CANCER THERAPY SALES, 2008 AND 2018
  • Table 81: ANTINEOPLASTIC MABS MARKET, 2008 AND 2014
  • Table 82: U.S. PERSONALIZED MEDICINE MARKET, THROUGH 2016
  • Table 83: U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, THROUGH 2016
  • Table 84: GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2016
  • Table 85: GLOBAL IVD MARKET, THROUGH 2016
  • Table 86: NEXT-GENERATION CANCER DIAGNOSTIC PRODUCTS BY TYPE, THROUGH 2016
  • Table 87: ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010 - 2016
  • Table 88: GLOBAL INCIDENCE OF ESTROGEN RECEPTOR POSITIVE BREAST CANCER CASES, 2010 - 2016
  • Table 89: PREDICTIVE TECHNOLOGY
  • Table 90: BREAST CANCER DIAGNOSTIC TEST COSTS
  • Table 91: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, THROUGH 2016
  • Table 92: IHC AND FISH-BASED BREAST CANCER TESTING SALES, THROUGH 2016
  • Table 93: FDA-APPROVED COMMERCIAL KITS
  • Table 94: FDA-APPROVED FISH ANALYSIS TESTS
  • Table 95: ROCHE SALES BY DIVISION, 2010
  • Table 96: ROCHE COMPANION DIAGNOSTICS CURRENTLY ON THE MARKET OR IN LATE DEVELOPMENT FOR BREAST CANCER
  • Table 97: GENOMIC MARKET LEADERS
  • Table 98: GENOMIC TESTING MARKET FOR BREAST CANCER, THROUGH 2016
  • Table 99: ONCOTYPE DX SALES, THROUGH 2016
  • Table 100: QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, THROUGH 2016
  • Table 101: RESULTS OF A SURVEY BY MEDCO AND THE AMERICAN MEDICAL ASSOCIATION, 2009

List of Figures

  • Summary Figure: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2010 - 2016
  • Figure 1: GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2008
  • Figure 2: ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010 - 2016
  • Figure 3: U.K. ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
  • Figure 4: GERMAN ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
  • Figure 5: CHINESE ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
  • Figure 6: INDIA ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
  • Figure 7: U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
  • Figure 8: GLOBAL PHARMACEUTICAL SALES, 2010 - 2016
  • Figure 9: BREAST CANCER THERAPY SALES, 2010 - 2016
  • Figure 10: BREAST CANCER DRUG MARKET, 2010 AND 2016
  • Figure 11: U.S. PERSONALIZED MEDICINE MARKET, 2010 - 2016
  • Figure 12: U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, 2010 - 2016
  • Figure 13: NEXT-GENERATION CANCER DIAGNOSTIC PRODUCTS BY TYPE, 2010 - 2016
  • Figure 14: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, 2010 - 2016
  • Figure 15: IHC AND FISH-BASED BREAST CANCER TESTING SALES, 2010 - 2012
  • Figure 16: GENOMIC TESTING MARKET FOR BREAST CANCER, 2010 - 2016
  • Figure 17: QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, 2010 - 2016
Show More
RELATED REPORTS
* EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023
  • Published:
  • Sep 10, 2014
  • USD 3995
  • 70 Pages

* Cancer Diagnostics: New Developments, Market Growth and Opportunities in the use of Circulating Tumour Cells and Circulating Nucleic Acids
  • Published:
  • Sep 08, 2014
  • USD 3016
  • 170 Pages

* Next-Generation Cancer Diagnostics: Technologies and Global Markets
  • Published:
  • Aug 31, 2014
  • USD 6650
  • 274 Pages

* Future Horizons and Growth Strategies in the European Cancer Diagnostics Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 22, 2014
  • USD 12800
  • 820 Pages

* Future Horizons and Growth Strategies in the German Cancer Diagnostics Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 22, 2014
  • USD 4350
  • 570 Pages

* Future Horizons and Growth Strategies in the Global Cancer Diagnostics Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 22, 2014
  • USD 21100
  • 1200 Pages

* Future Horizons and Growth Strategies in the Japanese Cancer Diagnostics Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 22, 2014
  • USD 4900
  • 590 Pages

* Future Horizons and Growth Strategies in the UK Cancer Diagnostics Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 22, 2014
  • USD 4350
  • 565 Pages

* Future Horizons and Growth Strategies in the US Cancer Diagnostics Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 22, 2014
  • USD 6400
  • 620 Pages

* Breast Cancer Partnering 2009-2014
  • Published:
  • Aug 01, 2014
  • USD 995

Browse more Cancer Market Research Reports

Pricing
Get Notified
Email me when related reports are published